The Colombian Association of Comprehensive Medicine Companies (Acemi) published a report on the shortage of medicines in Colombia, according to the report provided by the EPS that are in the union and serve 34 million patients.
These organizations reported a reduction in the supply of 1,242 active ingredients, which would configure a crisis in drugs. According to experts, the phenomenon that is being experienced today is not new and was warned since mid-2022.
The executive president of Acemi, Paula Acosta, acknowledged that there is a delicate reading in the sector due to the lack of medicines. However, there are some medical conditions that scare them more intensely, such as mental disorders in patients.
“We are especially concerned regarding the availability of multiple key active ingredients to guarantee the adequate treatment of people with chronic conditions, especially drugs for the treatment of mental disorders,” he said.
Also antibiotics and analgesics in general terms. This information provided by this Colombian Association is supported by some data published this week by the National Institute for Food and Drug Surveillance (Invima).
When the magnifying glass is put on the study published this weekend by Acemi, it is concluded that the group that is exposed to the drug crisis are those diagnosed with high blood pressure, then those with mental disorders and pain.
Although the list of patients at risk is longer. The warnings cover people with cardiovascular disorders, contraception, cancer, epilepsy, diabetes, HIV, orphan diseases, pulmonary hypertension and anticoagulation.
In the list appear, from greater to lesser scarcity, the presentations and commercial names: acetaminophen, amlodipine alone or in combination, amoxicillin, calcium alone or in combination, esomeprazole, pancreatin alone or in combination, and dexamethasone.
Similarly, quetiapine, montelukast, risperidone, immunoglobulin, mometasone, atorvastatin, levothyroxine, betamethasone, ezetimibe, fluticasone, levocetirizine, diclofenac, clindamycin, budesonide, olopatadine, meloxicam, and acetylcysteine.
“Implement mechanisms that improve communication between the actors that require the units and the number of units required, for the industry to know regarding it,” Acemi said in a press release.
Also have a system that allows the EPS to obtain real-time information on the availability of supply by the laboratories, in order to have a timely contract with the suppliers that have the availability of the products.
“Prioritize by Invima the procedures to obtain new sanitary registrations or their renewals. Define strategies to facilitate access to raw material. Update the price referencing methodology,” he added.
The document signed by the Association concluded that, although in the months of August and September 2022 there were working groups to analyze the problem with the Ministry of Health, they were not convened once more, while the crisis continued to gain strength with the days.
© 2023 SA Week Publications
SA Week Publications
Last News
Our brands
About us
Contact Us
Our App
Consumer Protection
Siganos:
Remember: The only accounts authorized to make deposits for the concept of subscriptions and renewals in the name of PUBLICACIONES SEMANA SA with NIT 860.509.265 -1, are: Banco de Bogotá: Current Account Number 00033073-8 Bancolombia: Savings Account Number 040- 359946-75
All registered trademarks are the property of the respective company or of PUBLICACIONES SEMANA SA The total or partial reproduction of any of the content that appears here is prohibited, as well as its translation into any language without the written authorization of its owner.
